Although the detailed mechanisms by which GLUT1-mediated glucose metabolism confers resistance to EGFR inhibitors on NSCLC cells remain to be elucidated in this study, the above hypothetical scenario implies that GLUT1 inhibition may be an authentic approach to overcoming the primary resistance of NSCLC cells without activating EGFR mutations to EGFR inhibitors. The gene discussed is SLC2A1; the disease is non-small cell lung carcinoma.